4/4
02:48 am
acxp
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 [Yahoo! Finance]
Medium
Report
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 [Yahoo! Finance]
3/19
11:02 am
acxp
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
3/18
07:01 am
acxp
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
High
Report
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
3/14
08:07 pm
acxp
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP [Yahoo! Finance]
Low
Report
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP [Yahoo! Finance]
3/10
04:30 pm
acxp
Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
Low
Report
Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
3/7
08:26 am
acxp
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering [Yahoo! Finance]
3/7
08:00 am
acxp
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
Medium
Report
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
3/3
08:06 am
acxp
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]
Medium
Report
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]
3/3
08:06 am
acxp
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]
Medium
Report
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]
3/3
08:00 am
acxp
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Medium
Report
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
3/3
08:00 am
acxp
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Medium
Report
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
3/3
08:00 am
acxp
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Medium
Report
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
2/28
08:00 am
acxp
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
Medium
Report
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
2/24
08:08 am
acxp
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI [Yahoo! Finance]
High
Report
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI [Yahoo! Finance]
2/24
08:00 am
acxp
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Medium
Report
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
2/24
08:00 am
acxp
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Medium
Report
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
2/24
08:00 am
acxp
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Medium
Report
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
2/19
09:05 am
acxp
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors [Yahoo! Finance]
Low
Report
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors [Yahoo! Finance]
2/19
08:00 am
acxp
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
Medium
Report
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
1/31
04:30 pm
acxp
Acurx Pharmaceuticals files for secondary offering [Seeking Alpha]
Medium
Report
Acurx Pharmaceuticals files for secondary offering [Seeking Alpha]